ABBV - AbbVie Inc.
| Previous Close | 67.52 |
| Open | 67.28 |
| Bid | 65.73 x 1200 |
| Ask | 65.97 x 800 |
| Day's Range | 65.48 - 67.79 |
| 52 Week Range | 62.66 - 98.70 |
| Volume | 8,718,506 |
| Avg. Volume | 10,687,781 |
| Market Cap | 97.535B |
| Beta (3Y Monthly) | 0.69 |
| PE Ratio (TTM) | 24.09 |
| EPS (TTM) | 2.74 |
| Earnings Date | Oct 31, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | 4.28 (6.34%) |
| Ex-Dividend Date | 2019-07-12 |
| 1y Target Est | 85.25 |
- Zacks
Amgen Presents Positive Data From Rituxan Biosimilar Study
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
- Zacks
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
- Simply Wall St.
Here's What You Should Know About AbbVie Inc.'s (NYSE:ABBV) 6.3% Dividend Yield
Today we'll take a closer look at AbbVie Inc. (NYSE:ABBV) from a dividend investor's perspective. Owning a strong...
- Zacks
Synlogic Discontinues Development of SYNB1020, Stock Down
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
- Barrons.com
AbbVie Stock Slipped to a New Low, and One Exec Scooped Up Shares
Jeffrey Ryan Stewart, the biopharmaceutical firm’s senior vice president of U.S. commercial operations, paid $1 million last week for stock trading near a 2½-year low.
- Investopedia
Pot Entrepreneurs Can Now Get an MBA in Cannabis
USciences says its program is first-of-its-kind and is offered as a track under the specialized pharma and healthcare MBA.
- Zacks
Bayer Sells Animal Health Division to Elanco: Now What?
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
- ETF Trends
The Time is Right For This Dividend ETF
With 10-year Treasury yields sliding lower and the Federal Reserve poised to lower interest rates again this year, perhaps multiple times, dividend stocks are an increasingly valuable asset class. Moreover, ...
- Barrons.com
Buy AbbVie Stock Because You ‘Can’t Ignore’ How Cheap It Is
Piper Jaffray argues the worst may finally be over for beleaguered AbbVie stock, and its price looks especially attractive.
- Zacks
Here's Why Allergan is Outperforming Its Industry Of Late
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
- Motley Fool
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.
- Investopedia
High-Dividend Stocks on Historic Discount as Yields Plunge, says Goldman
U.S. high-dividend stocks are trading at their biggest discount in four decades as investors flock to bonds, pushing down their yields.
- Investor's Business Daily
Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks?
Looking for stocks to buy? Get analysis of large-cap stocks like Amazon, Alibaba and Dow Jones stocks GE and Microsoft to see if it's time to buy — or sell.
- Investing.com
AbbVie Rises 3%
Investing.com - AbbVie (NYSE:ABBV) rose by 3.05% to trade at $66.39 by 12:56 (16:56 GMT) on Monday on the NYSE exchange.
- Zacks
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
- Motley Fool
5 Biggest New Drug Approvals Potentially on the Way in 2019
FDA approvals for these drugs could translate to billions of dollars for a few companies.
- Investor's Business Daily
How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit
Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.
- Investor's Business Daily
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
Merck stock jumped Friday after an analyst initiated coverage of the Dow Jones pharma giant with an outperform rating, citing "the Keytruda wave." Keytruda is a blockbuster cancer drug.
- MarketWatch
FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA
The U.S. Food and Drug Administration has approved AbbVie Inc's Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate hasn't worked, AbbVie announced Friday. The pharmaceutical company said Rinvoq should be available in the U.S. later this month. "Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity - the primary treatment goals for rheumatoid arthritis," said Roy Fleischmann, a clinical professor at the University of Texas Southwestern Medical Center at Dallas who led one of AbbVie's clinical trials of Rinvoq. "With this FDA approval, Rinvoq has the potential to help additional people living with RA achieve remission who have not yet reached this goal." The European Medicines Agency and regulatory authorities in Canada and Japan are still reviewing the drug. Shares of AbbVie were up 2.2% Friday afternoon, though they've fallen 30% in the year to date amid investor worry over declining sales of the company's blockbuster drug Humira. The stock also took a hit in June when the AbbVie said it would be acquiring Botox-maker Allergan Plc in a deal worth around $63 billion. The S&P 500 has gained 15.2% so far this year.
- Investor's Business Daily
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
- Reuters
UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr
AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. A four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year. Humira brought in global revenue of $4.87 billion in the second quarter, but sales have been hit by competition from cheaper rivals in Europe, and AbbVie in June announced a deal to buy Botox-maker Allergan Plc for $63 billion to reduce dependence on the drug.
- PR Newswire
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis - Durable remission rates with RINVOQ (as ...
- Zacks
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
- Investopedia
The Top Pharma Stocks for 2019
Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.
